Lily Akmar1, Michelle Cunnell2, Charles Kelly1, Josef Kovarik1, Muhammad Shahid Iqbal1. 1. Department of Clinical Oncology, Northern Centre for Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 2. Department of Medical Oncology, Northern Centre for Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Abstract
OBJECTIVES: To assess the efficacy of the second measured glomerular filtration rate (GFR) during the course of weekly cisplatin-based chemoradiotherapy in head and neck cancer. METHODS: Data was collected on consecutive 221 head and neck cancer patients who underwent cisplatin-based chemoradiotherapy. RESULTS: 68% patients managed to complete at least five out six proposed cycles of cisplatin, with a cumulative dose of ≥200 mg/m2. 181 patients underwent second measured GFR and it showed a mean fall in measured GFR by 12.0 ml/min/1.73 m2 (p < 0.0001). Out of these 181 patients, in 16 patients (9%), the decision to discontinue cisplatin was purely based on a low second measured GFR (below 50 ml/min/1.73 m2). CONCLUSION: Our study has shown that obtaining a second measured GFR is valuable in 9% of these patients. We propose that this should be considered as a standard procedure in these settings and also should be considered incorporating this additional safety measure, into future clinical trials as a mandatory procedure. ADVANCES IN KNOWLEDGE: To the best of author's knowledge, this is first study of its kind. The results of our study suggest that it should be a standard procedure of obtaining a second GFR in these settings.
OBJECTIVES: To assess the efficacy of the second measured glomerular filtration rate (GFR) during the course of weekly cisplatin-based chemoradiotherapy in head and neck cancer. METHODS: Data was collected on consecutive 221 head and neck cancer patients who underwent cisplatin-based chemoradiotherapy. RESULTS: 68% patients managed to complete at least five out six proposed cycles of cisplatin, with a cumulative dose of ≥200 mg/m2. 181 patients underwent second measured GFR and it showed a mean fall in measured GFR by 12.0 ml/min/1.73 m2 (p < 0.0001). Out of these 181 patients, in 16 patients (9%), the decision to discontinue cisplatin was purely based on a low second measured GFR (below 50 ml/min/1.73 m2). CONCLUSION: Our study has shown that obtaining a second measured GFR is valuable in 9% of these patients. We propose that this should be considered as a standard procedure in these settings and also should be considered incorporating this additional safety measure, into future clinical trials as a mandatory procedure. ADVANCES IN KNOWLEDGE: To the best of author's knowledge, this is first study of its kind. The results of our study suggest that it should be a standard procedure of obtaining a second GFR in these settings.
Authors: Neife Aparecida Guinaim dos Santos; Maria Augusta Carvalho Rodrigues; Nadia Maria Martins; Antonio Cardozo dos Santos Journal: Arch Toxicol Date: 2012-03-01 Impact factor: 5.153
Authors: Petr Szturz; Kristien Wouters; Naomi Kiyota; Makoto Tahara; Kumar Prabhash; Vanita Noronha; Ana Castro; Lisa Licitra; David Adelstein; Jan B Vermorken Journal: Oncologist Date: 2017-05-22
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: N Janus; V Launay-Vacher; E Byloos; J-P Machiels; L Duck; J Kerger; W Wynendaele; J-L Canon; W Lybaert; J Nortier; G Deray; H Wildiers Journal: Br J Cancer Date: 2010-11-09 Impact factor: 7.640
Authors: Muhammad Shahid Iqbal; Cheng Chaw; Josef Kovarik; Shahzeena Aslam; Aaron Jackson; John Kelly; Werner Dobrowsky; Charles Kelly Journal: Int Arch Otorhinolaryngol Date: 2016-12-19
Authors: Waheeda Owadally; Chris Hurt; Hayley Timmins; Emma Parsons; Sarah Townsend; Joanne Patterson; Katherine Hutcheson; Ned Powell; Matthew Beasley; Nachi Palaniappan; Max Robinson; Terence M Jones; Mererid Evans Journal: BMC Cancer Date: 2015-08-27 Impact factor: 4.430